Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $10.81 USD
Change Today -0.395 / -3.53%
Volume 1.9M
ZIOP On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

ziopharm oncology inc (ZIOP) Snapshot

Open
$11.19
Previous Close
$11.21
Day High
$11.24
Day Low
$10.79
52 Week High
03/20/15 - $14.40
52 Week Low
10/8/14 - $2.31
Market Cap
1.4B
Average Volume 10 Days
4.4M
EPS TTM
$-0.31
Shares Outstanding
128.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZIOPHARM ONCOLOGY INC (ZIOP)

ziopharm oncology inc (ZIOP) Related Bloomberg News

View More Bloomberg News

ziopharm oncology inc (ZIOP) Related Businessweek News

No Related Businessweek News Found

ziopharm oncology inc (ZIOP) Details

ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Its synthetic immuno-oncology programs, in collaboration with Intrexon Corporation and the MD Anderson Cancer Center, comprise chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use both non-viral and viral gene transfer methods for broad scalability. The company is also developing programs in various stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System(r) technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. Its pipeline includes various gene and cell-based therapeutics in both clinical and pre clinical testing which are focused on hematologic and solid tumor malignancies. ZIOPHARM Oncology, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

27 Employees
Last Reported Date: 02/26/15
Founded in 2003

ziopharm oncology inc (ZIOP) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $600.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $230.3K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $411.3K
Compensation as of Fiscal Year 2013.

ziopharm oncology inc (ZIOP) Key Developments

ZIOPHARM Oncology, Inc. and Intrexon Corporation Enters into Worldwide License and Collaboration Agreement with ARES Trading S.A

On March 27, 2015, ZIOPHARM Oncology, Inc. and Intrexon Corporation entered into a worldwide License and Collaboration Agreement or the Ares Trading Agreement with ARES Trading S.A. through which the parties established a collaboration for the research and development and commercialization of Products for the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans. The Ares Trading Agreement provides for the establishment of committees composed of Ares Trading and Intrexon representatives that will govern activities in, among others, the areas of project establishment, research plans and intellectual property. The Ares Trading Agreement grants Ares Trading an exclusive, worldwide, royalty-bearing, sub-licensable license under the company's and Intrexon's patents, know-how and proprietary platform of research tools and technology necessary for the company and Intrexon to perform their tasks directed towards the design, identification, culturing, and/or production of genetically modified cells to generate and test Chimeric Antigen Receptor T-Cell Products solely for the development, regulatory approval and commercialization of Products containing such Chimeric Antigen Receptor T-Cell Products pursuant to the licenses granted in clauses (b) and (c) of this paragraph; develop and commercialize Products in the Field, worldwide, provided that such Products are not Out-of-Scope Products where Ares Trading has not exercised its Option; and commercialize the chimeric antigen receptor for Products. Ares Trading will pay an upfront fee of $115.0 million to Intrexon as consideration for entry into the Ares Trading Agreement. Intrexon will pay 50% of the fee to the company in accordance with the ECP Amendment. Ares Trading will, pursuant to the terms of the Ares Trading Agreement, pay Intrexon certain fees for the research and development activities related to the products.

ZIOPHARM Oncology and Intrexon Synthetic Immuno-Oncology Programs Strengthened Through Collaboration With Merck Serono

ZIOPHARM Oncology, Inc. and Intrexon Corporation announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono. Intrexon will share the economic provisions of this collaboration, including upfront payment, milestones and royalties, equally with ZIOPHARM. Under the collaboration Merck Serono will elect CAR-T targets, two initially, for which it will provide certain research funding. Through its agreement with Intrexon, ZIOPHARM will be responsible for any additional research and development expenditures. Once these candidates reach investigational new drug (IND) stage, the programs will be transferred to Merck Serono for clinical development and commercialization. ZIOPHARM and Intrexon will also independently conduct research and development on other CAR-T candidates, with Merck having the opportunity during clinical development to opt-in. ZIOPHARM's other oncology programs will continue through its Exclusive Channel Collaboration (ECC) with Intrexon.

ZIOPHARM Oncology, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

ZIOPHARM Oncology, Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenue of $340,000 compared to $200,000 a year ago. Loss from operations was $10,596,000 compared to $6,719,000 a year ago. Net loss was $10,401,000 or $0.09 per basic and diluted share compared to $8,903,000 or $0.09 per basic and diluted share a year ago. For the year, the company reported revenue of $1,373,000 compared to $800,000 a year ago. Loss from operations was $43,499,000 compared to $57,713,000 a year ago. Net loss was $31,781,000 or $0.31 per basic and diluted share compared to $57,107,000 or $0.66 per basic and diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZIOP:US $10.81 USD -0.395

ZIOP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $23.34 USD -0.27
Dynavax Technologies Corp $23.31 USD -0.38
Exact Sciences Corp $21.98 USD -1.07
Genocea Biosciences Inc $12.24 USD -0.26
Inovio Pharmaceuticals Inc $10.35 USD -0.25
View Industry Companies
 

Industry Analysis

ZIOP

Industry Average

Valuation ZIOP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 839.6x
Price/Book 34.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,015.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZIOPHARM ONCOLOGY INC, please visit www.ziopharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.